Antibody-drug conjugates, or ADCs, are a class of biopharmaceutical drugs designed as targeted therapies for the treatment of cancer.
Neha Rathod Godbole, Senior Analyst at Vantage Market Research, explains that "the CDA market is growing rapidly, driven by the rising incidence of cancer worldwide and the increasing demand for targeted therapies offering greater efficacy and fewer side effects compared to traditional treatments.". "Recent approvals of ADCs, such as Enhertu for breast cancer, underline their potential to transform treatment landscapes in oncology."
She notes that the ADC sector is also seeing an increase in investment and strategic collaborations. "Big Pharma is increasingly partnering with biotech companies to leverage cutting-edge technologies and accelerate the development of next-generation ADCs." "These alliances promote not only innovation, but also the scalability and commercial viability of ADC products."
This is particularly true of Biotheus, a clinical-stage company focused on developing therapies for oncology and inflammatory diseases and included in the Vintage Altaroc Odyssey , which announced a few months ago the expansion of its partnership with Hansoh Pharmaceutical Group.
The collaboration between the two China-based companies involves upfront and potential payments of RMB 5 billion ($694.8 million) to Biotheus. Biotheus will grant Hansoh a license to use its Phase I antibody PM1080/HS-20117 to develop ADC therapies.
.webp)
%2520(1).webp)
